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  14 
Abstract 15 
Community-acquired pneumonia (CAP) is an important respiratory disease and the fifth 16 
leading cause of mortality in Europe. The development of molecular diagnostic tests has 17 
highlighted the contributions of respiratory viruses to the aetiology of CAP, suggesting 18 
the incidence of viral pneumonia may have been previously underestimated. We 19 
performed a systematic review and meta-analysis to describe the overall identification 20 
of respiratory viruses in adult patients with CAP in Europe, following PRISMA guidelines 21 
(PROSPERO; CRD42016037233).  We searched EMBASE, MEDLINE, CINAHL, WHOLIS, 22 
COCHRANE library and grey literature sources for relevant studies, and screened these 23 
against protocol eligibility criteria. Two researchers performed data extraction and risk of 24 
bias assessments, independently, using a piloted form. Results were synthesised 25 
narratively, and random effects meta-analyses performed to calculate pooled 26 
estimates of effect; heterogeneity was quantified using I2. Twenty-eight studies met 27 
inclusion criteria of which 21 were included in the primary meta-analysis. The pooled 28 
proportion of patients with identified respiratory viruses was 22.0% (95% CI: 18.0%-27.0%), 29 
rising to 29.0% (25.0%–34.0%) in studies where polymerase chain reaction (PCR) 30 
diagnostics were performed. Influenza virus was the most frequently detected virus in 9% 31 
(7%-12%) of adults with CAP. Respiratory viruses make a substantial contribution to the 32 
aetiology of CAP in adult patients in Europe; one or more respiratory viruses are 33 
detected in about one quarter of all cases.  34 
  35 
Introduction 36 
Community-acquired pneumonia (CAP) is a principal cause of excess hospitalisation 37 
and mortality worldwide1-3. Historically, the overriding clinical approach to the 38 
management of CAP has been to focus on bacterial aetiologies, with Streptococcus 39 
pneumoniae the dominant pathogen 4-8. More recently, coupled to the increasing 40 
availability of polymerase chain reaction (PCR) tests, the identification of viral pathogens 41 
in the aetiology of CAP has increased. Contemporary studies identify that viruses may 42 
be implicated in 15%-30% of all CAP9-11; in turn this heightens the possibility that empirical 43 
antibiotic treatment of CAP in the absence of adequate testing for viral pathogens may 44 
contribute to inappropriate antibiotic usage12,13.  45 
 46 
Given the considerable variation across individual studies in estimating the contribution 47 
of respiratory viruses to CAP aetiology, reliable summaries of relevant data are necessary 48 
to inform future research and policy initiatives, particularly as new respiratory virus 49 
vaccines and antiviral drugs are anticipated in the short to medium term11,14-17.  50 
Two recent systematic reviews of studies investigating the proportions of viral pathogens 51 
in patients with CAP focussed on studies that only used polymerase chain reaction 52 
(PCR)-based assays to detect viral pathogens and pooled results from studies 53 
conducted across the world.18,19  We report an additional systematic review of studies 54 
conducted within the World Health Organization European Region, which offers 55 
additional granularity according to setting, timing of study , viral diagnostic techniques 56 
and study quality. 57 
 58 
  59 
Methods 60 
The study protocol was registered on the National Institute for Health Research 61 
International Prospective Register of Systematic Reviews (PROSPERO; CRD42016037233; 62 
available at: 63 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037233) and 64 
conducted according to Preferred Reporting Items for Systematic Reviews and Meta-65 
Analyses (PRISMA) guidelines 20  66 
 67 
Eligibility criteria 68 
We identified studies which investigated the aetiology of CAP in adults in Europe 69 
(defined as those countries covered by the WHO Regional Office for Europe 70 
http://www.euro.who.int/en/countries) and reported quantitative data on the 71 
identification of respiratory viruses. We searched for original articles describing 72 
longitudinal studies or case series, in English, which investigated adults aged ≥16 years 73 
diagnosed with CAP. All other study designs were excluded. We included studies that 74 
performed either PCR or non-PCR detection techniques. 75 
We excluded studies of paediatric populations and patients residing in nursing homes, 76 
residential care homes or rehabilitation facilities. Studies of adults diagnosed with CAP 77 
based on clinical signs but without radiologic confirmation, and studies focused on CAP 78 
in adults with severe immunosuppression through disease and/or drug treatment were 79 
also excluded.  80 
 81 
 82 
 83 
 84 
Search strategy and screening 85 
The following electronic databases were systematically searched: EMBASE, MEDLINE, 86 
CINAHL, WHOLIS, and Web of Science from January 1999 to April 2016.  A 87 
comprehensive search strategy was developed for EMBASE (Supplementary Appendix 88 
1) and subsequently adjusted as required to suit other databases. The reference lists of 89 
all eligible articles were manually searched to identify other eligible studies. 90 
All identified articles were imported to ENDNOTE software X4 (Thomson Reuters, Toronto, 91 
CA, USA) and duplicates removed. Two review authors (YA and JSN-V-T) independently 92 
screened the retained articles against protocol eligibility criteria, in three stages: by title, 93 
abstract and full text. Any disagreements were resolved through discussion between YA 94 
and JSN-V-T; and a third author (WSL) adjudicated over any outstanding discrepancies.  95 
 96 
Data extraction and Risk of Bias assessment 97 
Data extraction for each eligible study was also performed independently by YA and 98 
JSN-V-T using a pre-piloted data extraction form using Microsoft® Office Excel® 2010 99 
(Microsoft Corporation, Richmond, VA, USA). For all included studies, information was 100 
extracted on: author(s); year of publication; country; healthcare setting; number of 101 
evaluable patients; viral diagnostic techniques employed; samples collected for virus 102 
detection; number of respiratory virus pathogens tested for; and number and proportion 103 
of respiratory viruses detected. YA and JSN-V-T independently assessed the quality of all 104 
included studies, using criteria adapted from the Newcastle – Ottawa scale for 105 
observational studies21, focusing on three key domains: representativeness of patient 106 
population; ascertainment of CAP diagnosis; and ascertainment of virus aetiology. We 107 
awarded zero or one star in each domain; for representativeness, one star was awarded 108 
for studies sampling from the general community (as opposed to more specialised 109 
patient subgroups); for ascertainment of CAP diagnosis we awarded one star for 110 
independent radiographic confirmation of diagnosis; and for virus aetiology, one star for 111 
use of ‘gold standard’ PCR diagnostic techniques. 112 
 113 
 114 
Summary measures, and analysis 115 
The proportion of respiratory viruses identified in evaluable CAP patients was pooled 116 
using the generic inverse variance approach, based on a random effects model 117 
(DerSimonian- Laird weights method)22, stabilising the variances using the Freeman-118 
Tukey double arcsine transformation so that studies with proportions close to 0% or 119 
100% were appropriately estimated23. Exact binomial confidence intervals were 120 
computed for outcomes. The primary outcome was the overall contribution of 121 
respiratory viruses in the aetiology of CAP, calculated as the total number of patients 122 
with respiratory viruses identified (numerator) as a proportion of the total number of 123 
evaluable patients (denominator). We report, as secondary outcomes, the contribution 124 
of individual viruses calculated as the total number of patients with individual respiratory 125 
viruses identified as a proportion of all evaluable patients for each specific pathogen.  126 
Heterogeneity between studies was quantified using the I2 statistic23. We investigated 127 
potential sources of heterogeneity by performing subgroup analyses; by study setting 128 
(inpatient vs. outpatient), study quality, viral diagnostic methods used (PCR diagnostic 129 
techniques vs non-PCR methods) and mixed infections (bacterial and viral infections). All 130 
analyses were conducted with the  metaprop commands within Stata (V.13, Stata Corp, 131 
College Station, Texas, USA). 132 
Results 133 
We identified a total of 1106 articles from database searches, reducing to 1083 after the 134 
removal of duplicates. Eleven additional papers were identified via citation tracking. 135 
After screening, 27 articles remained within protocol eligibility criteria (Figure 1); one of 136 
the included articles25 presented two separate studies and data from both were 137 
extracted and presented separately. Thus, 28 studies from 27 articles were included in 138 
the systematic review25-51, and 21 from 20 in the primary meta-analysis25-44. When 139 
examined as full-text articles, seven studies did not present sufficient quantitative data 140 
for inclusion in the primary meta-analysis45-51 (Figure 1). 141 
 142 
Study characteristics 143 
All 28 studies included in the systematic review were prospective or retrospective 144 
longitudinal studies or case-series.  The patient population size in each ranged from 71 to 145 
1356 (total=8,777). The earliest publications were in 200137,40, and the most recent article 146 
was published in October 201526. 147 
 Studies from 11 different European countries were included of which Spain was most 148 
frequently represented (9 studies; 32.1%)27,28,31,33,41,44,47,50,51. Nineteen studies* (67.9%)25,26,29-149 
32,35,36,39-44,47-50 were carried out among inpatient populations (n=5,515 patients), 150 
three34,38,46 (10.7%) in outpatient/community populations (n=524 patients) and six 151 
(21.4%)27,28,33,37,45,51 in mixed populations (n=2,738 patients). Details of the characteristics 152 
of the included studies are summarised in Table 1. Sixteen studies (57.1%) 26,29,30,32,34-36,39,41-153 
45,47,49,50 had used PCR techniques for the detection of respiratory viruses, alone or in 154 
combination with other diagnostic methods. 14 studies (50%) obtained upper respiratory 155 
samples26,28,30,35,36,38,39,41-44,46,49,50, 16 (57.1%) lower respiratory25,31-34,38,42,43,45-51(nine 156 
publications), and six (21.4%) both38,42,43,46,49,50 . In 10 (35.7%) studies (9 publications) 157 
respiratory tract sampling was combined with assessment of paired serology25,31-33,45,46,49-158 
51; and in four (14.3%) studies, serology alone was performed27,29,37,40. 159 
                                       
* Citation #25 describes two studies 
 160 
Risk of bias assessment 161 
Study population representativeness, diagnostic accuracy of CAP and ascertainment of 162 
virus aetiology were assessed with a maximum of three stars per study. Eleven 163 
studies26,30,32,34-36,39,41-43,45(39.3%) were assessed as being at low risk of bias (three stars; 164 
one star per domain), 14† studies25,26,29,33,37,38,40,44,46,47,49-51 (53.6%) at moderate risk of bias 165 
(2 out of 3 stars), and three28,31,48 (7.1%) were at high risk of bias (one or zero stars). Six 166 
studiesa (21.4%) reported difficulty in obtaining adequate samples for microbiological 167 
testing25,27,32,37,41. Within-study variation in viral diagnostic methods across different study 168 
years was reported in ten studies (35.7%)26,29,30,35,36,39,41-44. 169 
 170 
Overall identification of respiratory viruses 171 
The percentage of respiratory viruses detected in CAP patients ranged from 6% in a 172 
Spanish study comprising both inpatients and outpatients33, to 45% in a study of 173 
hospitalised patients in Israel42. By meta-analysis, the pooled proportion of respiratory 174 
viruses detected in CAP patients was 22.0% (95% CI 17.0%-27.0%; I2=94.7%) (Figure 2).   175 
 176 
There was a significant trend for the identification of respiratory virus pathogens to be 177 
lower in studies (n=8)a published from 2001 to 200925,31-34,37,40, (pooled estimate=14.0% 178 
(95%CI 9.0%-21.0%)) compared with more recent studies (n=13) published after 201026-179 
30,35,36,38,39,41-44 (pooled estimate=27.0% (95%CI 20.0%-33.0%)), test for subgroup differences, 180 
p=0.007 (Supplementary Appendix 2).  181 
 182 
Sub-group analyses  183 
The pooled proportion of respiratory viruses identified among inpatient studies (n=15) 184 
25,26,29-32,35,36,39-44with CAP was 27.0% (95% CI 23.0%-31.0%; I2=85.1%); compared with 19.0% 185 
                                       
† Citation #25 describes two studies 
(95% CI 14.0%-24.0%; I2=95.3%) for outpatient studies (n=2)34,38, and 9.0% (95% CI 6.0%-186 
12.0%; I2 =85.8%) in two studies with mixed populations (n=4)27,28,33,37  (Figure 3). Each of 187 
these populations revealed results that were statistically significantly different from each 188 
other (test for subgroup differences, p<0.01). Studies with mixed populations27,28,33,37, relied 189 
exclusively on non-PCR diagnostic methods and were of lower quality compared to other 190 
studies.  191 
 192 
The pooled proportion of respiratory viral pathogens identified in 12 studies26,29,30,32,34-36,38,41-193 
44 using PCR (with or without additional testing methods) was 29.0% (95% CI 25.0%–34.0%, 194 
I2=83.5%) compared with 13.0% (95% CI 9.0%–18.0%, I2=90.7%) in nine studies using other 195 
non-PCR methods25,27,28,31,33,37,38,40, with a significant difference between the two groups, 196 
p<0.001 (Figure 4).  197 
 198 
In lower risk of bias studies (NOS score=3 stars )26,30,32,34-36,39,41-43the pooled proportion for 199 
total respiratory viral pathogens was 30%, (95% CI 25%–34%, I2=77.4%), compared with 11% 200 
(95% CI 9%-13%, I2=99.3%) in higher risk of bias studies (NOS score=1 star)28,31, explaining the 201 
observed heterogeneity between studies, p<0.001 (Figure 5). 202 
 203 
Mixed Infections 204 
The pooled proportion of mixed respiratory viruses and bacterial co-infections detected 205 
in CAP patients was 10% (95% CI 6%-14%, I2=94.7%) reported across 14 studies 26-29,32,33,35-206 
37,40-44 (Figure 6).   207 
 208 
Individual viruses 209 
Data on the seven most common respiratory viruses identified are presented in Table 2. 210 
Influenza viruses were most frequently detected (9%), followed by rhinoviruses (5%) and 211 
coronaviruses (4%); together accounting for the majority of respiratory viruses detected 212 
(Table 2).  213 
 214 
Discussion 215 
This review updates evidence on the microbiological identification of respiratory viral 216 
pathogens in adult patients with radiographically confirmed CAP in Europe. Overall our 217 
data suggest that respiratory viruses are detectable in at least 22% of radiologically 218 
confirmed CAP cases, mostly hospitalised cases. However significantly higher proportions 219 
of respiratory viruses were evident in studies conducted after 2010 (27%), studies that 220 
included viral PCR techniques (29%), and studies assessed to be at lower risk of bias (29%), 221 
suggesting that the true proportion of CAP associated with respiratory viruses is at least 222 
one quarter (25%). Our findings accord with recent major studies or reviews conducted in 223 
Asia and North America 11,14,52,53. In the CDC EPIC study11, viruses were detected in 27.0% 224 
of adult patients with CAP, while Qu et al. detected viruses in 27.5% of Asian patients with 225 
CAP51.  226 
 227 
Our review suggests that in Europe, as in other parts of the world, a relatively large burden 228 
of CAP disease may be attributable to viral infections. However, the clinico-pathological 229 
significance of virus detection in patients with CAP remains uncertain. A clear limitation of 230 
our approach (and of each of the included studies) is that no proof is offered that the 231 
virus or viruses identified were of pathological significance in all cases. There was also 232 
heterogeneity between studies in terms of the respiratory sites sampled and/or use of 233 
serology. Viruses recovered from upper respiratory tract (URT) sites might have less 234 
pathological significance than those recovered from lower respiratory tract (LRT) sites; 235 
nevertheless, in the absence of concomitant sampling from URT and LRT it is not possible 236 
to disregard viruses identified from URT sites which may have been replicated in the LRT if 237 
it had also been sampled. Whilst respiratory viruses are undoubtedly implicated in the 238 
aetiology of a substantial proportion of the cases in which they are detected, 239 
asymptomatic illness associated with virus shedding is well recognised, especially in 240 
children who experience longer periods  of shedding than adults54. In addition, modern 241 
PCR diagnostic techniques are comparatively more sensitive than methods for the 242 
detection of bacteria and capable of detecting small quantities of nucleic acid which 243 
may not in all cases represent culturable virus; therefore, some patients with ‘viral-only’ 244 
pathogens identified may also have a microbiologically unrecognised bacterial infection; 245 
and some detections of viral pathogens may represent previous or resolved virus infection.  246 
In a recent study, Gadsby et al.  employed PCR techniques to identify bacteria as well as 247 
viruses from lower respiratory tract samples, viruses were detected in 30% of 323 adults 248 
admitted to hospital with CAP and a co-bacterial pathogen was detected in 82% of 249 
these55. In contrast we noted only 10% of cases with a bacterial co-pathogen; this might 250 
reflect the use of PCR testing for bacteria by Gadsby and colleagues, whereas the studies 251 
we included used standard approaches for the identification of bacteria. The detection 252 
of respiratory viruses in healthy asymptomatic individuals is not as extensively described as 253 
in symptomatic patients; nevertheless Jartti and colleagues summarised data from 51 254 
studies, noting maximum baseline prevalences of respiratory viruses as follows: 255 
rhinoviruses, 15%; adenoviruses, 5.3%; influenza, 4.3%; RSV, 2.6%; coronaviruses, 2.5%; 256 
eneteroviruses 1.2%; human bocavirus, 1.1%; parainfluenza, 0.9%; and hMPV, 0.6%54. 257 
Jansen and colleagues have observed that rhinovirus is extremely common in 258 
asymptomatic children (28%), but that if other viruses are identified, notably RSV, 259 
adenoviruses and hMPV, these are much more likely to be clinically relevant56; this may 260 
be different in adults. We lacked direct comparison with any such ‘asymptomatic control’ 261 
group in the included studies, nor did we have access to data on the host response to 262 
viruses in individual subjects. However separate studies in asymptomatic patients54,56 offer 263 
important contextualization for our findings; and inclusion of an asymptomatic 264 
comparator group would be likely to add granularity in future studies. 265 
 266 
Since previous work identified high heterogeneity in the extant literature from other parts 267 
of the world,18,19 we expected this and decided, a priori,  that high heterogeneity would 268 
not preclude meta-analysis. We were unable to identify a single clear reason for the 269 
observed high heterogeneity which we attribute to multiple factors including study quality 270 
(Figure 5), variable settings, patient populations, sampling sites, and diagnostic methods; 271 
disease severity and co-infections with other pathogens. Since rhinovirus and Respiratory 272 
syncytial virus (RSV) RSV infections have a predilection for asthmatic patients57,58, 273 
underlying comorbidities may have influenced our findings.  274 
 275 
Influenza (9%) viruses, rhinoviruses (5%) and coronaviruses (4%) accounted for the majority 276 
of virus detections; these proportions are similar to the estimates reported previously by 277 
Burk et al and Wu et al18,19. However, RSV was identified in only 2% of adult CAP which 278 
may be relevant to the potential role of future RSV vaccines targeted at the elderly. 279 
 280 
These findings highlight the importance of respiratory viruses in the aetiology of adult CAP, 281 
and the potential relevance of our findings towards improving clinical outcomes, and 282 
reducing inappropriate antibiotic use. Influenza appears to be the most significant virus 283 
pathogen, followed by rhinoviruses and coronaviruses. Notwithstanding, different 284 
included studies looked for between 4-11 separate respiratory viruses (Table 1); if all 285 
included studies had tested for all 11 viruses the overall proportion of virus detection may 286 
well have been considerably higher, although, as discussed above, not all detections 287 
necessarily have clinical relevance to CAP. This potential source of bias will not have 288 
affected the estimates for individual viruses (Table 2) because these analyses were 289 
organism-specific and based on all available data by organism. Viral diagnostic 290 
evaluation of CAP facilitates greater precision in the assessment of illness severity, and the 291 
tailoring of therapy, in particular the rapid use of neuraminidase inhibitors for cases of 292 
influenza and more judicious use of antibiotics. Since there are realistic near-term 293 
prospects for novel antiviral treatments for several respiratory virus infections and RSV 294 
vaccines59-61, there is a need to establish baseline data on the incidence of viral CAP and 295 
develop a wider culture of testing for respiratory virus pathogens without which it will be 296 
difficult to assess the impact of advances in therapy. 297 
 298 
We included only articles reported in English. An analysis including country-specific data 299 
reported in other languages may reveal regional variations in the contribution of 300 
respiratory viruses to the microbiology of CAP.  Although, the effect of age was 301 
considered as an important source of heterogeneity, a sub-analysis by age could not be 302 
performed due to the lack of detailed reporting of study results by age groups; this may 303 
have influenced our results. Similarly, subgroup analyses could not be performed 304 
according to patient illness severity, patient comorbidities, type of respiratory sample or 305 
the presence of specific bacterial co-pathogens due to lack of data. Publication bias 306 
applies when studies reporting ‘positive’ findings are more likely to be published than 307 
those reporting ‘negative’ findings and is an important consideration in meta-analyses 308 
evaluating treatment effects. However, in the context of studies examining the 309 
proportion of CAP patients in whom viruses were detected, well-conducted ‘negative’ 310 
studies are as ‘surprising’ as ‘positive’ studies and both would be expected to be 311 
published. The first study to examine the use of standard publication bias tests for 312 
proportional meta-analyses (such as this one) found that funnel plots and statistical tests 313 
potentially yield misleading results, especially where the proportions within the studies 314 
are either very high or very low62. These researchers describe an alternative method that 315 
can be used to explore the potential for publication bias, where the sample size is used 316 
instead of the standard error for each study; however, the reliability and accuracy of this 317 
method has yet to be fully explored and independently validated. Therefore, we 318 
elected not to analyses publication bias.   319 
 320 
Conclusion  321 
This systematic review suggests that, in Europe, respiratory viruses are identifiable in at 322 
about one quarter of all adults presenting with CAP. Of these, the most frequently 323 
identified pathogens are influenza viruses, rhinoviruses and coronaviruses, accounting for 324 
over one half of all identified viral pathogens. Further study to determine the importance 325 
of identifying viral pathogens in relation to treatment with antibiotics or antivirals is 326 
warranted.   327 
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‡ One article presented data on two separate studies25 
Records identified through database searching 
(n=1106) 
Records after duplicates removed 
(n=1083) 
 
Records screened by title and 
abstract  
(n=1083) 
Records excluded 
(n=1029) 
Full-text articles assessed for 
eligibility 
(n=54 ) 
 
Full-text articles excluded, with 
reasons 
(n = 38) 
 
Reasons for exclusion: 
 
 Abstract only i.e. no 
full text available 
(insufficient data), n=4 
 Insufficient data on 
viral pathogens, n=9 
 Reviews and editorials 
(no new data), n=4 
 In vitro study, n=1 
 No clear cut distinction 
between adult and 
paediatric data, n=6 
 Data on viral 
pathogens were not 
clearly presented, n=7 
 Poor case definition of 
CAP i.e. no chest 
radiography, n=5 
 Full text in Turkish with 
no translation, n=1 
 Study reported only 
one non-respiratory virus 
(Varicella Zoster), n=1 
 
 
 
 
 
 
 
 
 
 
 
Articles included in qualitative 
synthesis 
(n = 27 articles; 28 studies)* 
Studies included in quantitative 
synthesis (meta-analysis) 
(n = 20 articles; 21 studies)* 
Additional articles identified 
through  
citation tracking (n=11) 
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Figure 2: Forest plot: overall identification of respiratory viruses in European 
adult patients with CAP. 
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Figure 3: Forest plot: overall identification of respiratory viruses in European 
patients with CAP, stratified by study setting. 
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Figure 4: Forest Plot: overall identification of respiratory viruses in European 
patients with CAP, by diagnostic method employed 
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Figure 5: Forest plot: overall identification of respiratory viruses in European 
patients with CAP, according to study quality 
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Figure 6: Forest plot: mixed respiratory virus and bacterial co-infections in 
European patients with CAP.
Table 1: Characteristics of included studies. 
First author Study 
setting 
Study 
design  
Patient 
characteristic
s  
Total 
number 
of 
patient
s with 
CAP 
Numbe
r of 
viruses 
tested 
for 
Male % Diagnostic methods Principal study focus  Specime
n sites* 
Le Bel [2015] 
26  
France, 
inpatients  
Prospectiv
e cohort 
Patients aged 
>18 years 
presented to 
Emergency 
dept. 
319 8  101 
(31.7%) 
PCR Inflammatory 
biomarkers in CAP 
patients 
UR 
Capelastegu
i [2011] 27  
Spain, 
inpatients 
and 
outpatients 
Prospectiv
e cohort 
Patients aged 
>18 years in 
the 
community 
and hospital 
700 5 Not 
reported 
Blood cultures, 
urinary antigen tests, 
serology, direct 
immunofluorescence 
antibody assay 
Aetiology of CAP S 
Cilloniz [2012] 
28 
Spain, 
inpatients 
and 
outpatients 
Prospectiv
e cohort 
Patients aged 
>16 years 
admitted to 
the 
Emergency 
wards and 
outpatients. 
568 5 301 
(53.0%) 
Serology, blood 
culture, antigen tests. 
Aetiology of CAP UR 
Clark [2014]29  UK, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
hospital with 
acute 
respiratory 
infection but 
166  9 87(52.4%) Blood and Sputum 
culture, PCR 
Aetiology of ARI in 
adults 
S 
subset with 
CAP patients 
Das [2015]30 France, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the 
Emergency 
dept. 
125  7 Not 
reported 
PCR Aetiology of CAP UR 
de Roux 
[2004]31  
Spain, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
hospital 
1356 5 893(65.8%
) 
Serology, 
complement fixation 
kit tests for viruses. 
Viral CAP in non-
immunocompromise
d adults 
LR, S 
 
 
 
Diederen 
[2001]32  
Netherlands
, 
Inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
242 8 7(2.9%) PCR, serology, ELISA Detection of 
respiratory pathogens 
using PCR 
LR, S 
Guiterrez 
[2005]  33 
Spain, 
inpatients 
and 
outpatients 
Prospectiv
e cohort 
Patients aged 
>15 years 
admitted to 
the hospital 
493 5 308(62.5%
) 
Blood and sputum 
cultures, 
complement fixation 
tests. 
Investigating the 
influence of age and 
gender on the 
incidence of CAP 
LR, S 
Holm [2007]34  Denmark, 
outpatients 
Prospectiv
e cohort 
Patients aged 
>18 years with 
CAP 
presenting to 
the GP 
48 6 28(58.3%) PCR Aetiology of CAP LR 
Holter 
[2015]35  
Norway , 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
267 8 140(52.4%
) 
Culture, serology, 
PCR 
Aetiology of CAP in 
Norway 
UR 
Howard-a 
[2004] 25 
UK, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>15 years  
69 Not 
reported 
6(8.7%) Complement fixation 
tests, blood culture 
Not reported LR, S 
Howard-b 
[2004] 25  
UK, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>16 years  
99 Not 
reported 
6(6.1%) Complement fixation 
tests, blood culture 
Aetiology of CAP  LR,S 
Johansson 
[2015]36  
Sweden, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
184 9 94(51.1%) Culture, PCR, 
Serology 
Aetiology of CAP UR 
Joikinen 
[2001] 37 
Finland, 
inpatients 
and 
outpatients  
Prospectiv
e cohort 
Patients aged 
>15 years 
admitted to 
the hospital 
and patients 
in the 
community 
 
345   7 176(51.0%
) 
Serology  Aetiology of CAP in 
adults in Eastern 
Finland 
S 
Koksal [2010]  
38 
Turkey, 
outpatients 
Cross –
sectional 
Patients aged 
>17 years with 
CAP in 
outpatient 
settings 
292 6 147(50.3%
) 
Culture, direct 
immunofluorescence
, serology 
Aetiology of CAP in 
adults in Turkey 
UR, LR 
Liberman 
[2010] 39 
Israel, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
183  8 105(57.4%
) 
PCR Evaluate the role of  
respiratory viruses in 
adult CAP 
UR 
Lim [2001] 40  UK, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>16 years 
admitted to 
the hospital 
267 5 135(50.6%
) 
Other conventional 
methods 
Investigate the 
aetiology of CAP and 
implication for CAP 
management 
S 
Sangil 
[2012]41  
Spain, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
169 9 Not 
reported 
PCR, serology  Aetiology of CAP 
using PCR and other 
UR 
admitted to 
the hospital 
conventional 
methods. 
Shibli [2010] 
42 
Israel, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
127 6 73(57.5%) PCR, DNA & RNA 
extraction, Serology 
Investigate the 
aetiology of CAP in 
hospitalised patients . 
UR, LR 
van 
Gageldonk-
Lafeber 
[2013]43  
Netherland, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
presented to 
the 
Emergency 
dept. 
339 9 212(62.5%
) 
Culture , serology, 
antigen tests, PCR 
Aetiology of CAP  UR, LR 
Viasus [2014] 
44 
Spain, 
inpatients 
Prospectiv
e cohort 
Adult patients 
admitted to 
the hospital 
747 8  PCR, Serology Aetiology of CAP UR 
Templeton 
[2005] 45 
 
Netherlands
, inpatients 
and 
outpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
136 Not 
reported 
75(55.1%) Culture, PCR, 
Serology 
Aetiology of CAP LR, S 
Bochud 
[2001]46  
Switzerland, 
outpatients 
Prospectiv
e cohort 
Patients aged 
>15 years  
184  4 82(44.6%) Serology Aetiology of CAP in 
outpatients 
UR, LR, S 
Marcos 
[2006] 47  
Spain, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>14 years 
admitted to 
the hospital 
198 7 Not 
reported 
PCR, 
immunofluorescence 
and culture 
Aetiology of CAP LR 
Hohenthal 
[2004] 48  
Finland, 
inpatients 
Prospectiv
e cohort 
Patients aged 
>18 years 
admitted to 
the hospital 
71 7 48(67.6%) Culture Diagnostic value of 
BAL  
LR 
Huijskens 
[2013]49 
Netherland , 
inpatients 
Prospectiv
e 
Patients aged 
>18 years 
408 11 250(61.3%
) 
PCR , Culture and 
serology 
to differentiate pure 
bacterial, pure viral UR, LR, S 
 presented to 
the 
emergency 
dept. 
and mixed viral 
and bacterial 
aetiologies based on 
clinical signs 
admission 
Cilloniz [2011] 
50 
 
Spain, 
Inpatients 
 >18 years with 
CAP admitted 
to ICU within 
24hrs 
362 5 232(64.1%
) 
Immunofluorescence
, PCR 
polymicrobial 
pneumonia UR, LR, S 
Almirall 
[2007] 51 
 
Spain, 
inpatients 
and 
outpatients 
 >14 years, 216 
patients were 
managed at 
home and 
280 patients 
were 
admitted to 
hosp.  
496 7  Culture, serology, 
Immunofluorescence 
Differences in 
aetiology of CAP LR, S 
Specimen sites: UR=upper respiratory tract; LR= lower respiratory tract; S=serological assessment (using paired sera). *In studies which sampled from >1 site, not 
all patients will have undergone sampling at all sites
 Virus type Pooled % 95% CI No. of studies (and patients) included in 
pathogen-specific meta-analysis 
I2(%) 
Influenza (A or B) 9 7-12 17 (6,487) 93.45 
Rhinovirus 5 4-7 12 (3,324) 88.22 
Coronavirus 4 2-7 7 (1,343) 80.37 
Parainfluenza 3 2-5 14 (5,600) 88.35 
Human 
metapneumovirus 
(hMPV) 
2 1-2 10 (1,779) 7.49 
Respiratory syncytial 
virus (RSV) 
2. 1-3 17 (5,968) 82.42 
Adenovirus 1 0-1 13 (3,166) 32.88 
 
Enterovirus, poliovirus, cytomegalovirus, coxsackie virus, varicella-zoster virus, human bocavirus and herpes simplex virus were detected in <1% of adult patients with CAP. 
Table 2: Summary of individual pathogen-specific meta-analyses for respiratory viruses most commonly identified in European adult 
patients with CAP
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1. virus.mp. or virus/ 
2. exp virus pneumonia/et [Etiology] 
3. exp Adenoviridae/ 
4. exp Coronavirus/ or exp SARS coronavirus/ 
5. exp Influenzavirus B/ or exp Influenzavirus A/ or exp Influenzavirus C/ 
6. exp influenza/ or exp influenza B/ or exp Influenza B virus/ or exp influenza C/ or exp Influenza C virus/ or exp 
influenza A/ or exp Influenza A virus/ 
7. exp Parainfluenza virus infection/ 
8. exp Human respiratory syncytial virus/ 
9. exp Rhinovirus/ or exp Human rhinovirus/ or exp Rhinovirus infection/ 
10. exp Human metapneumovirus/ 
11. exp Human metapneumovirus/ or exp Metapneumovirus infection/ or exp Metapneumovirus/ or exp Human 
metapneumovirus infection/ 
12. Nipah virus/ or exp Paramyxovirinae/ 
13. (virus* or viral or (influenza or flu) or (parainfluenza or paraflu) or (metapneumovirus or hmpv) or adenovirus or 
(respiratory and syn* and virus*) or rsv or rhinovirus or coronavirus).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
15. exp community acquired pneumonia/ep, et [Epidemiology, Etiology] 
16. exp infectious pneumonia/ep, et [Epidemiology, Etiology] 
17. (community and acquired and pneumonia).mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] 
18. (community-acquired and pneumonia).mp. [mp=title, abstract, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, keyword] 
19. 15 or 16 or 17 or 18 
20. exp Europe/ or exp Eastern Europe/ or exp Western Europe/ or exp Southern Europe/ 
21. exp Spain/ or exp Eastern Europe/ or exp Europe/ or exp France/ or exp Italy/ or exp United Kingdom/ or exp 
Germany/ 
 37 
 3 
 4 
22. exp United Kingdom/ or exp France/ or exp Europe/ or exp Netherlands/ or exp European/ or exp Italy/ or exp 
Germany/ 
23. (albania or andorra or armenia or austria or azebaijan or belarus or belgium or herzegovina or bulgaria or croatia 
or cyrus or czech or denmark or estonia or finland or france or georgia or germany or greece or hungary or iceland or 
ireland or israel or italy or kazakhstan or kyrgyzstan or latvia or lithuania or luxembourg or malta or monaco or 
montenegro or netherlands or norway or poland or portugal or moldova or romania or russia * or san marino or serbia 
or slovakia or spain or sweden or switzeland or tajikistan or macedonia or turkey or turkmenistan or ukraine or england 
or wchartales or scotland or united kingdom or Uk or uzbekistan).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, keyword] 
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ES = effect size for pooled identification of respiratory viruses 9 
 10 
Appendix 2: Forest plot: overall identification of respiratory viruses in European patients 11 
with CAP, by study year 12 
